New Drug Targets Extreme Hunger, Revealing Obesity's Complexity
A new drug, Vykat XR, approved for Prader-Willi syndrome, offers hope for controlling extreme hunger caused by genetic factors, highlighting the complexity of obesity and the need for targeted treatments. However, federal funding cuts threaten ongoing research into obesity and rare diseases, potentially hindering future breakthroughs.